IDH2 and acute myeloid leukemia: With the understanding of biological and clinical properties of mutated isoforms of IDH 1 and IDH2, inhibitors ivosidenib and enasidenib have been developed to teat AML (Platt et al., 2015; Halik et al., 2022).